MEDIROM Healthcare TechnologiesvsStarbucks

MRM and SBUX stock compared: price, dividend, valuation and results, from SEC filings.

MEDIROM Healthcare Technologies (MRM) has a market value of $1.8M and Starbucks (SBUX) $118B. Over the last year, with dividends, MRM moved -88.9% and SBUX +26.2%. Dividend yield: MRM none, SBUX 2.41%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRM$1.8M

    SBUX$118B

    SBUX is 64,694 times MRM

  • Revenue, 12 months

    MRM$50M

    SBUX$37.9B

    SBUX is 766 times MRM

  • Net income, 12 months

    MRM-$23M

    SBUX$2.5B

  • Operating margin

    MRM-43.7%

    SBUX9.7%

    53.4 points apart

  • ROIC

    MRM–

    SBUX36.2%

  • P/E

    MRM–

    SBUX46.5

  • Dividend yield

    MRM0.0%

    SBUX2.4%

    2.4 points apart

  • 5-year return

    MRM-97.0%

    SBUX+5.0%

    102.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRM-97.0%

SBUX+5.0%

05010020222023202420252026
Returns by period
PeriodMRMWith dividendsSBUXWith dividends
1 year since November 19, 2025-88.9%Price -88.9%+26.2%Price +23.2%
3 years since November 20, 2023-95.3%-63.9% a yearPrice -95.3%+6.7%+2.2% a yearPrice -1.1%
5 years since November 19, 2021-97.0%-50.4% a yearPrice -97.0%+5.0%+1.0% a yearPrice -6.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRMMEDIROM Healthcare TechnologiesSBUXStarbucks

Valuation

MRMSBUX
Valuation
Price$0.23$103.13
Market value$1.8M$118B
Enterprise value (EV)–$127B
P/E–46.5
P/E, 5-year median21.829.8
P/B––
EV/EBIT–34.4
Free cash flow yield–3.2%

Results and growth

MRMSBUX
Results and growth
Revenue, 12 months$50M$37.9B
Net income, 12 months-$23M$2.5B
Free cash flow, 12 months-$7.4M$3.7B
Earnings per share, 12 months-$2.93$2.21
Revenue growth, year on year-6.5%2.0%
Revenue growth a year, past+18.4%over 5 years+5.5%over 5 years
EPS growth a year, past–-9.0%over 5 years

Margins and returns on capital

MRMSBUX
Margins and returns on capital
Gross margin––
Operating margin-43.7%9.7%
Net margin-46.8%6.7%
ROIC–36.2%
ROE––

Balance sheet

MRMSBUX
Balance sheet
Cash$625.9K$3.9B
Total debt–$22.4B
Net debt / EBITDA–1.8
Interest cover–7.0×

Dividends and buybacks

MRMSBUX
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$2.49
Dividend growth a year, past–+1.7%over 5 years
Buyback yield––
Shareholder yield–2.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRM or SBUX

Didn't find what you were looking for?

Ask us
Which is bigger, MEDIROM Healthcare Technologies or Starbucks?

By market value, Starbucks ($118B) is about 64,694.3 times MEDIROM Healthcare Technologies ($1.8M), at today's prices.

How did MRM and SBUX stock do over the last 5 years?

Since November 19, 2021, MRM's price moved -97.0% and SBUX's -6.9%. With dividends: MRM -97.0% (-50.4% a year), SBUX +5.0% (+1.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRM or SBUX?

The dividend yield at today's price is none for MEDIROM Healthcare Technologies and 2.41% for Starbucks. Over the last twelve months they paid – and $2.49 per share.

Which has the higher profit margins, MEDIROM Healthcare Technologies or Starbucks?

Over the last twelve months, the net margin was -46.8% for MEDIROM Healthcare Technologies and 6.7% for Starbucks, and the operating margin -43.7% and 9.7%. Revenue was $50M and $37.9B.

Which is the better investment, MEDIROM Healthcare Technologies or Starbucks?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.